4/21
10:48 am
nuvl
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting [Yahoo! Finance]
Low
Report
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting [Yahoo! Finance]
4/21
10:32 am
nuvl
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
Low
Report
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
4/21
08:14 am
nuvl
Nuvalent (NUVL) had its "buy" rating reaffirmed by HC Wainwright. They now have a $155.00 price target on the stock.
Low
Report
Nuvalent (NUVL) had its "buy" rating reaffirmed by HC Wainwright. They now have a $155.00 price target on the stock.
4/17
04:54 pm
nuvl
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 [Yahoo! Finance]
Low
Report
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 [Yahoo! Finance]
4/17
04:01 pm
nuvl
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
Low
Report
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
4/8
08:49 am
nuvl
Nuvalent (NUVL) had its "outperform" rating reaffirmed by Wedbush. They now have a $125.00 price target on the stock.
Low
Report
Nuvalent (NUVL) had its "outperform" rating reaffirmed by Wedbush. They now have a $125.00 price target on the stock.
4/7
06:30 am
nuvl
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
Low
Report
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
3/30
08:43 am
nuvl
Nuvalent (NUVL) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $116.00 price target on the stock.
Low
Report
Nuvalent (NUVL) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $116.00 price target on the stock.
3/26
07:34 am
nuvl
S&P 500 Futures Drop in Premarket Trading; Nuvalent, Figure Tech Solns Lead [Barron's]
Low
Report
S&P 500 Futures Drop in Premarket Trading; Nuvalent, Figure Tech Solns Lead [Barron's]
3/17
05:32 pm
nuvl
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 [Yahoo! Finance]
Low
Report
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 [Yahoo! Finance]
3/17
05:15 pm
nuvl
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026
Low
Report
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026
3/16
08:34 pm
nuvl
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally [Yahoo! Finance]
Low
Report
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally [Yahoo! Finance]
3/11
10:43 am
nuvl
Assessing Nuvalent (NUVL) Valuation After Widening Losses And A New US$458.4m Shelf Registration [Yahoo! Finance]
Low
Report
Assessing Nuvalent (NUVL) Valuation After Widening Losses And A New US$458.4m Shelf Registration [Yahoo! Finance]
2/27
09:47 am
nuvl
Nuvalent (NUVL) had its price target raised by Cantor Fitzgerald from $135.00 to $140.00. They now have an "overweight" rating on the stock.
Low
Report
Nuvalent (NUVL) had its price target raised by Cantor Fitzgerald from $135.00 to $140.00. They now have an "overweight" rating on the stock.
2/26
06:55 am
nuvl
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Low
Report
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
2/26
06:30 am
nuvl
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results
Low
Report
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results
2/20
01:26 pm
nuvl
Nuvation Bio: Why Ibtrozi's 6x Adoption Rate Changes The Thesis (Rating Upgrade) [Seeking Alpha]
Low
Report
Nuvation Bio: Why Ibtrozi's 6x Adoption Rate Changes The Thesis (Rating Upgrade) [Seeking Alpha]
2/9
08:37 am
nuvl
Assessing Nuvalent (NUVL) Valuation As DCF Signals Upside Versus Current Market Pricing [Yahoo! Finance]
Low
Report
Assessing Nuvalent (NUVL) Valuation As DCF Signals Upside Versus Current Market Pricing [Yahoo! Finance]
2/5
06:30 am
nuvl
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Medium
Report
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026